Published March 9, 2020
| Version v1
Journal article
Prognostic Value and Therapeutic Implication of Laparoscopic Extraperitoneal Paraaortic Staging in Locally Advanced Cervical Cancer: A Spanish Multicenter Study
Creators
- 1. Universitat de Barcelona. Institute Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) (Spain)
- 2. Hospital Universitario. Department of Obstetrics and Gynecology (Spain)
- 3. Complejo Hospitalario Universitario Insular-Materno Infantil. Department of Gynecologic Oncology (Spain)
- 4. Hospital Universitario La Paz. Department of Gynecology (Spain)
- 5. Hospital Universitario Donostia. Service of Gynecology and Obstetrics (Spain)
- 6. Hospital Universitari i Politècnic La Fe. Department of Gynecology Oncology (Spain)
- 7. Universitat Autònoma de Barcelona. Department of Obstetrics and Gynecology, Hospital de la Santa Creu I Sant Pau (Spain)
- 8. Hospital General Universitari de Castelló. Department of Obstetrics and Gynecology (Spain)
- 9. Universidad Complutense de Madrid. Women's Health Institute, Hospital Clínico San Carlos (Spain)
- 10. Universidad de Valencia. Department of Obstetrics and Gynecology, Hospital General Universitario de Valencia (Spain)
- 11. Universitat Autònoma de Barcelona. Gynecological Oncology Department, Hospital Universitari Vall d'Hebron (Spain)
Description
Purpose
: To assess the impact of laparoscopic extraperitoneal paraaortic staging in therapeutic planning and prognosis of patients with locally advanced cervical cancer (LACC) as compared with imaging staging.Methods
: Retrospective multicenter study of stage IB2 and IIA2 to IVA (FIGO 2009) LACC patients who were candidates for primary chemoradiotherapy. The study (surgical) group included 634 patients undergoing laparoscopic/robotic extraperitoneal paraaortic staging treated with extended-field radiotherapy (EFRT) if lymph node involvement was confirmed. The control (imaging) group included 288 patients treated with EFRT when lymph node involvement was suspected on positron emission tomography-computed tomography scans and/or magnetic resonance imaging.Results
: In the study group, a median of 13 (range 9–17) lymph nodes were removed, with a rate of positive paraaortic nodes of 18%, with metastatic size ≤ 5 mm in 20.4% of cases. Paraaortic EFRT was administered to 18% of patients in the study group and in 58% of controls. In 34% of patients from the surgical group, EFRT was modified according to surgical findings with respect to imaging staging. The median follow-up in the study and control groups was 3.7 and 4.8 years, respectively. In both groups, the overall survival and cancer-specific disease-free survival were similar. The time interval between diagnosis and starting EFRT was 18 days longer in the study group, without differences in overall survival as compared with controls (hazard ratio 1.00, 95% confidence interval 0.998–1.005; p = 0.307).Conclusions
: Laparoscopic extraperitoneal paraaortic staging in LACC patients is safe and modified therapeutic planning, allowing better selection of candidates for EFRT.Additional details
Identifiers
Publishing Information
- Journal Title
- Annals of Surgical Oncology (Online)
- Journal Volume
- 27
- Journal Issue
- 8
- Journal Page Range
- p. 2829-2839
- ISSN
- 1534-4681
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 55059486
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CHEMOTHERAPY; COMBINED THERAPY; DIAGNOSIS; LYMPH NODES; METASTASES; NEOPLASMS; NMR IMAGING; PATIENTS; PLANNING; POSITRON COMPUTED TOMOGRAPHY; PROCTITIS; RADIOTHERAPY; SIZE; SPECIFICITY; SURGERY; SURVIVAL CURVES
- Descriptors DEC
- COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DIGESTIVE SYSTEM DISEASES; DISEASES; EMISSION COMPUTED TOMOGRAPHY; LYMPHATIC SYSTEM; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; THERAPY; TOMOGRAPHY
Optional Information
- Copyright
- Copyright (c) 2020 © Society of Surgical Oncology 2020